文献速递临床试验与 GCP

印度高血压双药治疗比较:一项随机临床试验

Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial.
PubMed 文献 · Nat Med · 2025-07-25

在印度开展的多中心单盲试验中,1981名30-79岁高血压患者按1:1:1随机接受氨氯地平-培哚普利、培哚普利-吲达帕胺或氨氯地平-吲达帕胺单片复方制剂治疗。6个月时三种方案均使24小时动态收缩压大幅下降约14 mmHg,诊室血压下降约30/14 mmHg,约70%患者血压达标,组间无显著差异,耐受性均良好。

要点

  • 三种常用双药单片复方制剂在印度高血压患者中降压幅度相似,6个月动态收缩压均降约14 mmHg。
  • 诊室血压均降约30/14 mmHg,约70%患者达到坐位血压<140/90 mmHg的达标水平。
  • 日间、夜间动态血压及诊室血压和达标率等次要终点组间均无显著差异,耐受性均良好。

核心结论

  • 在印度患者中,氨氯地平-培哚普利、培哚普利-吲达帕胺和氨氯地平-吲达帕胺三种双药组合降压疗效相当且均耐受良好。

研究设计与样本

  • 多中心、单盲随机临床试验在印度开展,纳入30-79岁(平均52岁)高血压患者。
  • 入组条件为未治疗者平均坐位收缩压150-179 mmHg,或单药治疗者收缩压140-159 mmHg。
  • 按1:1:1随机分配至氨氯地平-培哚普利、培哚普利-吲达帕胺或氨氯地平-吲达帕胺单片复方制剂组。
  • 共纳入1981名参与者(女性42%),其中1637名完成6个月24小时动态血压测量。
  • 主要终点为6个月时24小时动态收缩压平均变化。

主要发现

  • 三种药物组合均使主要终点大幅下降,6个月时动态血压约降14/8 mmHg,诊室血压约降30/14 mmHg。
  • 三种组合的坐位血压<140/90 mmHg达标率均约为70%。
  • 日间和夜间动态血压、诊室血压及达标率等次要终点组间均无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evidence is lacking for guiding optimal combination hypertension therapy in South Asian patients. Here we investigated the blood pressure (BP)-lowering efficacy and safety of three commonly recommended antihypertensive dual combinations in a multicenter, single-blinded trial conducted in India. We randomized Indians aged 30-79 years (mean age, 52 years) with mean sitting systolic blood pressure (SBP) of 150-179 mmHg on no treatment or an SBP of 140-159 mmHg on monotherapy 1:1:1 to a single-pill combination of amlodipine-perindopril, perindopril-indapamide or amlodipine-indapamide. The primary outcome was the mean change in 24-hour ambulatory SBP at 6 months. Of the 1,981 participants (42% females) enrolled in the trial, 1,637 completed a 24-hour ambulatory BP measurement. All three drug combinations produced similar large reductions in the primary outcome, namely ambulatory (~14/8 mmHg) and office (~30/14 mmHg) BPs after 6 months, such that hypertension control rates (sitting BP < 140/90 mmHg) were achieved in approximately 70% of participants in all three groups. Furthermore, no significant differences in secondary outcomes, such as mean day and night ambulatory and office BPs and hypertension control rates, were observed among the study groups. Thus, in Indian patients, amlodipine-perindopril, perindopril-indapamide and amlodipine-indapamide were all equally well tolerated and equally highly effective in reducing 24-hour ambulatory and office BPs (ClinicalTrials.gov registration: NCT05683301 ).

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Prabhakaran D, Roy A, Chandrasekaran AM, et al. Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial. Nat Med. 2025. PMID: 40715816. doi:10.1038/s41591-025-03854-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。